AstraZeneca Archives -

Market Access/ News/ News/ News/ News/ Oncology/ Sales and Marketing

EU clears Enhertu for HER2-low breast cancer

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, her2, Oncology 0 Comment

The European Commission has approved Daiichi Sankyo and AstraZeneca’s Enhertu as the first targeted therapy for HER2-low breast

EU clears Enhertu for HER2-low breast cancer

https://pharmaphorum.com/news/eu-clears-enhertu-for-her2-low-breast-cancer/

News/ News/ News/ Oncology/ R&D

Merck’s Keytruda flunks another prostate cancer test

Phil Taylor AstraZeneca, biliary tract cancer, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Oncology, Prostate cancer 0 Comment

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co’s checkpoint inhibitor Keytruda is

Merck’s Keytruda flunks another prostate cancer test

https://pharmaphorum.com/news/mercks-keytruda-flunks-another-prostate-cancer-test/

Digital/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Ovarian cancer, Olivia, and the OCC – part one

Nicole Raleigh AstraZeneca, ENGAGe, ESGO, Olivia, ovarian cancer, Ovarian Cancer Coalition, patients 0 Comment

Following the European Society of Gynaecological Oncology (ESGO) 2022 congress, pharmaphorum spoke with experts from among the Ovarian

Ovarian cancer, Olivia, and the OCC – part one

https://pharmaphorum.com/views-and-analysis/ovarian-cancer-olivia-and-the-occ-part-one/

News/ News/ News/ Oncology/ Sales and Marketing

BMS lawsuit claims AZ’s Imjudo infringes Yervoy patents

Phil Taylor AstraZeneca, Bristol-Myers Squibb, Imjudo, litigation, patent litigation, Yervoy 0 Comment

AstraZeneca followed a long and arduous road to bring its CTLA4 inhibitor Imjudo to market, and will now

BMS lawsuit claims AZ’s Imjudo infringes Yervoy patents

https://pharmaphorum.com/news/bms-lawsuit-claims-azs-imjudo-infringes-yervoy-patents/

patient app and clinical trial support tool

Digital/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Driving clinical trial innovation forward with precision medicine

Nicole Raleigh AstraZeneca, clinical trials, digital health, patient app, precision medicine, Unify 0 Comment

Late last year, pharmaphorum spoke with AstraZeneca’s Ben Challis, VP and head of translational science and experimental medicine,

Driving clinical trial innovation forward with precision medicine

https://pharmaphorum.com/views-and-analysis/driving-clinical-trial-innovation-forward-with-precision-medicine/

Digital/ News/ News/ News/ News/ Oncology/ Patients

AstraZeneca backs AI-based lung cancer diagnosis pilot in UK

Phil Taylor AstraZeneca, diagnosis, digital, digital health, lung cancer, Oncology, Qure.ai 0 Comment

Drugmaker AstraZeneca has teamed up with Indian digital health specialist Qure.ai and a clinical group in the UK

AstraZeneca backs AI-based lung cancer diagnosis pilot in UK

https://pharmaphorum.com/news/astrazeneca-backs-ai-based-lung-cancer-diagnosis-pilot-in-uk/

Market Access/ News/ News/ News/ Sales and Marketing

EU clears AstraZeneca’s new-form severe asthma drug Tezspire

Phil Taylor asthma, AstraZeneca, regulatory approval, severe asthma, Tezspire 0 Comment

AstraZeneca’s first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation

EU clears AstraZeneca’s new-form severe asthma drug Tezspire

https://pharmaphorum.com/news/eu-clears-new-form-astrazenecas-severe-asthma-drug-tezspire/

Market Access/ News/ News/ News/ R&D

Avillion, AstraZeneca asthma rescue treatment given FDA approval

Nicole Raleigh Airsupra, asthma, AstraZeneca, Avillion, FDA approval, partnership, respiratory 0 Comment

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved

Avillion, AstraZeneca asthma rescue treatment given FDA approval

https://pharmaphorum.com/news/avillion-astrazeneca-asthma-rescue-treatment-given-fda-approval/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ R&D

AstraZeneca bolts on blood pressure drug with CinCor takeover

Phil Taylor AstraZeneca, cardiovascular, chronic kidney disease, CinCor Pharma, Farxiga, hypertension, M&A, nephrology 0 Comment

AstraZeneca has extended its cardiorenal pipeline with a $1.3 billion acquisition of CinCor Pharma, adding a late-stage blood

AstraZeneca bolts on blood pressure drug with CinCor takeover

https://pharmaphorum.com/news/astrazeneca-bolts-on-blood-pressure-drug-with-cincor-takeover/

Trending

AstraZeneca

Login